Globenewswire·2026-01-07 12:00Core Insights - Monte Rosa Therapeutics announced positive interim data from the Phase 1 clinical study of MRT-8102, a NEK7-directed molecular glue degrader aimed at treating inflammatory conditions linked to the NLRP3 inflammasome, IL-1, and IL-6 [2][3] Study Results - MRT-8102 demonstrated an 85% reduction in C-reactive protein (CRP) levels after four weeks of treatment, with 94% of participants achieving CRP values below 2 mg/L, indicating a lower cardiovascular disease (CVD) risk [1][3][8] - The study included single ascending dose (SAD) and multiple ascending dose (MAD) cohorts, showing deep and sustained NEK7 degradation across doses from 5 mg to 400 mg [1][3] - A favorable safety profile was observed, with mild to moderate adverse events and no increased infection risk reported [1][7] Future Development Plans - The ongoing GFORCE-1 study of MRT-8102 in subjects with elevated CVD risk is being expanded to include multiple dose levels, with results anticipated in the second half of 2026 [1][5] - A Phase 2 study (GFORCE-2) for MRT-8102 in atherosclerotic cardiovascular disease (ASCVD) is planned to be initiated in 2026 [1][5] - Additional indications for MRT-8102 are being evaluated, including metabolic dysfunction-associated steatohepatitis (MASH), gout, and recurrent pericarditis [3][5] Company Overview - Monte Rosa Therapeutics is a clinical-stage biotechnology company focused on developing highly selective molecular glue degrader (MGD) medicines for serious diseases, leveraging its QuEEN™ discovery engine [9]